Faruqi and Faruqui, LLP Logo
Share this page

Argos Therapeutics, Inc. (ARGS)

NASDAQ:ARGS

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc.  To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Argos Therapeutics, Inc. (“Argos” or the “Company”) (NASDAQ:ARGS) of the May 15, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of all those who purchased Argos securities between February 7, 2014 and February 21, 2017 (the “Class Period”).  The case, Maurer v. Argos Therapeutics Inc. et al, No. 1:17-cv-00216was filed on March 14, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Arcentis technology platform was not viable; (ii) ADAPT was likely to be discontinued, and (iii) as a result, the Company’s financial statements and statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Specifically, on February 22, 2017, prior to the market opening, Argos filed a Form 8-K with the Securities and Exchange Commission (“SEC”) announcing that the Independent Data Monitoring Committee for ADAPT recommended that the study be discontinued for futility, finding that the study was unlikely to demonstrate a statistically significant improvement in overall survival.

On this news, Argos’ share price fell from $4.40 per share on  February 21, 2017 to a closing price of $1.48 on February 22, 2017—a $2.92 or a 66.36% drop.

Take Action

If you invested in Argos securities between February 7, 2014 and February 21, 2017 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Argos’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Argos Therapeutics, Inc. (ARGS)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 03/16/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.